CN1344735A - Human testicular development specific protein-19 gene encoding protein - Google Patents
Human testicular development specific protein-19 gene encoding protein Download PDFInfo
- Publication number
- CN1344735A CN1344735A CN01127197A CN01127197A CN1344735A CN 1344735 A CN1344735 A CN 1344735A CN 01127197 A CN01127197 A CN 01127197A CN 01127197 A CN01127197 A CN 01127197A CN 1344735 A CN1344735 A CN 1344735A
- Authority
- CN
- China
- Prior art keywords
- gene
- nyd
- protein
- prepare
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 50
- 230000023508 male gonad development Effects 0.000 title abstract description 25
- 102000004169 proteins and genes Human genes 0.000 title abstract description 10
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 11
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 10
- 101000922061 Homo sapiens Beta-catenin-like protein 1 Proteins 0.000 claims abstract description 9
- 108700026244 Open Reading Frames Proteins 0.000 claims abstract description 7
- 102100031109 Beta-catenin-like protein 1 Human genes 0.000 claims abstract description 4
- 239000002299 complementary DNA Substances 0.000 claims abstract description 4
- 210000001550 testis Anatomy 0.000 claims description 10
- 239000002671 adjuvant Substances 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 2
- 241000283977 Oryctolagus Species 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 230000003248 secreting effect Effects 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 238000012408 PCR amplification Methods 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 238000012215 gene cloning Methods 0.000 abstract 2
- 230000002381 testicular Effects 0.000 abstract 1
- 238000011160 research Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 5
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000237988 Patellidae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 230000021595 spermatogenesis Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 102000004282 Ribosomal protein S9 Human genes 0.000 description 1
- 108090000878 Ribosomal protein S9 Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003509 anti-fertility effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 239000002871 fertility agent Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 101150019405 gene 19 gene Proteins 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明属于人类基因组技术领域,所述的人睾丸发育特异性蛋白－19基因(testis development specific protein gene 19,NYD－SP19)基因全长cDNA序列为1501bp,其开放阅读框序列为1131bp,其编码376个氨基酸,该基因在基因库(Genbank)中的编号为AF367471。本发明利用NYD－SP19基因克隆制备融合蛋白,并用该蛋白免疫动物制备单克隆和多克隆抗体,同时将基因克隆用于睾丸特异功能基因表达芯片的制备。The invention belongs to the field of human genome technology. The full-length cDNA sequence of the human testis development specific protein gene 19 (NYD-SP19) gene is 1501bp, its open reading frame sequence is 1131bp, and its coding 376 amino acids, the number of this gene in Genbank (Genbank) is AF367471. The invention utilizes NYD-SP19 gene cloning to prepare fusion protein, uses the protein to immunize animals to prepare monoclonal and polyclonal antibodies, and simultaneously uses gene cloning to prepare testicular specific function gene expression chips.
Description
一、技术领域1. Technical field
本发明属于人类基因组技术领域。The invention belongs to the technical field of human genome.
二、发明内容2. Contents of the invention
本发明所述人睾丸发育特异性蛋白-19基因(testis developmentspecific protein gene 19，NYD-SP19)是发明人在南京医科大学生殖医学江苏省重点实验室用基因芯片方法筛选获得，首先制备人睾丸功能基因表达芯片，通过比较胚胎和成年人睾丸功能基因的表达，获得差异表达克隆，经序列测定证明为全长cDNA，为1501bp；其开放阅读框架为1131bp，编码376个氨基酸。查阅基因库，该基因为新基因。由于该基因是成人睾丸高表达，胚胎睾丸低表达，因此发现的人睾丸发育特异性蛋白-19基因可能与睾丸发育，特别是精子发生有关，用该基因克隆可制备成融合蛋白，用该蛋白免疫家兔，可获得单克隆和多克隆抗体，该基因也可用于制备睾丸功能基因表达芯片。The human testis development specific protein gene-19 gene (testis development specific protein gene 19, NYD-SP19) described in the present invention was obtained by the inventor in the Key Laboratory of Reproductive Medicine, Jiangsu Province, Nanjing Medical University, through the gene chip method screening, and first prepared human testis function Gene expression chip, by comparing the expression of embryonic and adult testis functional genes, to obtain differentially expressed clones, which were proved by sequence determination to be full-length cDNA, which is 1501bp; its open reading frame is 1131bp, encoding 376 amino acids. Check the gene bank, the gene is new. Because the gene is highly expressed in adult testis and low in embryonic testis, the human testis development-specific protein-19 gene found may be related to testis development, especially spermatogenesis, and fusion protein can be prepared by cloning this gene. By immunizing rabbits, monoclonal and polyclonal antibodies can be obtained, and the gene can also be used to prepare a testis functional gene expression chip.
由于人睾丸发育特异性蛋白-19基因在Genbank数据库中尚无人的同源基因，本发明人对于该基因的结构和功能研究成果全都是开创性的。美国国家生物技术情报中心(National Center for BiotechnologyInformation，NCBI)已正式接受该基因为Genbank的新成员，接受号为AF367471。Since the human testis development-specific protein-19 gene has no homologous gene in the Genbank database, the inventors' research results on the structure and function of this gene are all groundbreaking. The National Center for Biotechnology Information (NCBI) has officially accepted the gene as a new member of Genbank with the acceptance number AF367471.
1 gggaagagtg ctgtggtgag tgagggattt tgccatggag aaggagaagg acccatagca1 gggaagagtg ctgtggtgag tgagggatt tgccatggag aaggagaagg acccatagca
61 gtttgtcagg ttcatggaat ccgagctgga cctaaatgac atcattcagg agatgcacgt61 gtttgtcagg ttcatggaat ccgagctgga cctaaatgac atcattcagg agatgcacgt
121 ggtggccacc atgccagacc tgtaccacct tctggtggag ctgaatgctg tacagtcgct121 ggtggccacc atgccagacc tgtaccacct tctggtggag ctgaatgctg tacagtcgct
181 tctcggcttg ctcggacacg ataatacaga tatcctttca gatctgacct cagtaggaga181 tctcggcttg ctcggacacg ataatacaga tatcctttca gatctgacct cagtaggaga
241 gctgacatgg tggatgggca ggtggtagca ctgctggtac agaatctgga gcgcctggat241 gctgacatgg tggatgggca ggtggtagca ctgctggtac agaatctgga gcgcctggat
301 gagtctgtga aagaggaggc agatggcgtc cacaacactc tggctattgt ggaaaacatg301 gagtctgtga aagaggaggc agatggcgtc cacaacactc tggctattgt ggaaaacatg
361 gctgagttcc ggcctgagat gtgtacagag ggtgcccagc agggtcttct acagtggctg361 gctgagttcc ggcctgagat gtgtacagag ggtgcccagc agggtcttct acagtggctg
421 ttgaagaggc tgaaggcaaa gatgcctttt gatgccaaca aactgtattg cagtgaagtg421 ttgaagaggc tgaaggcaaa gatgcctttt gatgccaaca aactgtattg cagtgaagtg
481 ctggccatat tgctccagga caatgatgaa aacagggaat tgcttgggga gctggatgga481 ctggccatat tgctccagga caatgatgaa aacagggaat tgcttgggga gctggatgga
541 atcgatgtgc ttcttcagca gttatccgtg tttaaaagac acaatcccag cacggctgag541 atcgatgtgc ttcttcagca gttatccgtg tttaaaagac acaatcccag cacggctgag
601 gagcaggaga tgatggagaa tctgtttgat tccctctgct cctgtctaat gcttagttcc601 gagcaggaga tgatggagaa tctgtttgat tccctctgct cctgtctaat gcttagttcc
661 aatcgtgagc gcttcctgaa gggcgagggt cttcagctga tgaatctcat gctcagggaa661 aatcgtgagc gcttcctgaa gggcgagggt cttcagctga tgaatctcat gctcagggaa
721 aagaagatct cccggagcag tgccctgaaa gtgctggacc atgccatgat tggccccgaa721 aagaagatct cccggagcag tgccctgaaa gtgctggacc atgccatgat tggccccgaa
781 ggcacagaca actgccataa gtttgttgac attcttggct tacgaaccat ctttcccctc781 ggcacagaca actgccataa gtttgttgac attcttggct tacgaaccat ctttcccctc
841 tttatgaaat ctcccaggaa gatcaagaaa gtgggaacca ctgagaagga acatgaagag841 tttatgaaat ctcccaggaa gatcaagaaa gtgggaacca ctgagaagga acatgaagag
901 catgtctgtt cgatcctggc ttccctcctg cggaacctga gagggcagca gcggacccgg901 catgtctgtt cgatcctggc ttccctcctg cggaacctga gagggcagca gcggacccgg
961 cttctgaata aattcactga aaatgacagt gagaaggttg acagactaat ggagttgcat961 cttctgaata aattcactga aaatgacagt gagaaggttg acagactaat ggagttgcat
1021 tttaaatatc tgggtgcaat gcaggtggcg gacaagaaga ttgaagggga aaaacacgac1021 tttaaatatc tgggtgcaat gcaggtggcg gacaagaaga ttgaagggga aaaacacgac
1081 atggtccggc gaggagagat catcgacaat gacaccgagg aggagttcta cctccggcgc1081 atggtccggc gaggagagat catcgacaat gacaccgagg aggagttcta cctccggcgc
1141 ctggatgcgg ggctctttgt tctccagcac atctgctaca tcatggccga gatctgcaat1141 ctggatgcgg ggctctttgt tctccagcac atctgctaca tcatggccga gatctgcaat
1201 gccaatgtcc cccagattcg ccagagggtt caccagatcc taaacatgcg aggaagctcc1201 gccaatgtcc cccagattcg ccagagggtt caccagatcc taaacatgcg aggaagctcc
1261 atcaaaattg tcaggcatat catcaaggag tatgcagaga acatcgggga cggccggagc1261 atcaaaattg tcaggcatat catcaaggag tatgcagaga acatcgggga cggccggagc
1321 ccggagttcc gggagaacga gcaaaagcgc atcctgggct tgctggagaa cttctagagg1321 ccggagttcc gggagaacga gcaaaagcgc atcctgggct tgctggagaa cttctagagg
1381 caccttggcc ctgcgcatca tggactctct cagcttccct cccaggatca gtttctacac1381 caccttggcc ctgcgcatca tggactctct cagcttccct cccaggatca gtttctacac
1441 aactctgtgt ggcttttgga caaattaaag ctagttttgg tttaaaaaaa aaaaaaaaaa1441 aactctgtgt ggcttttgga caaattaaag ctagttttgg tttaaaaaaaaaaaaaaaaa
1501 a1501a
人睾丸发育特异性蛋白-19基因cDNA序列MVDGQVVALLVQNLERLDESVKEEADGVHNTLAIVENMAEFRPEMCTEGAQQGLLQWLLKRLKAKMPFDANKLYCSEVLAILLQDNDENRELLGELDGIDVLLQQLSVFKRHNPSTAEEQEMMENLFDSLCSCLMLSSNRERFLKGEGLQLMNLMLREKKISRSSALKVLDHAMIGPEGTDNCHKFVDILGLRTIFPLFMKSPRKIKKVGTTEKEHEEHVCSILASLLRNLRGQQRTRLLNKFTENDSEKVDRLMELHFKYLGAMQVADKKIEGEKHDMVRRGEIIDNDTEEEFYLRRLDAGLFVLQHICYIMAEICNANVPQIRQRVHQILNMRGSSIKIVRHIIKEYAENIGDGRSPEFRENEQKRILGLLENF人睾丸发育特异性蛋白-19基因cDNA序列MVDGQVVALLVQNLERLDESVKEEADGVHNTLAIVENMAEFRPEMCTEGAQQGLLQWLLKRLKAKMPFDANKLYCSEVLAILLQDNDENRELLGELDGIDVLLQQLSVFKRHNPSTAEEQEMMENLFDSLCSCLMLSSNRERFLKGEGLQLMNLMLREKKISRSSALKVLDHAMIGPEGTDNCHKFVDILGLRTIFPLFMKSPRKIKKVGTTEKEHEEHVCSILASLLRNLRGQQRTRLLNKFTENDSEKVDRLMELHFKYLGAMQVADKKIEGEKHDMVRRGEIIDNDTEEEFYLRRLDAGLFVLQHICYIMAEICNANVPQIRQRVHQILNMRGSSIKIVRHIIKEYAENIGDGRSPEFRENEQKRILGLLENF
人睾丸发育特异性蛋白-19基因编码蛋白氨基酸序列Amino acid sequence of protein encoded by human testis development specific protein-19 gene
本发明的目的是：鉴于人睾丸发育特异性蛋白-19基因是本发明人发现的全新基因，目前人类对此基因的认识和了解仅限于本发明人所做的科学研究工作。由于该基因是与睾丸特异功能相关的基因，而且是胚胎低表达，成人高表达，因此该基因很可能与睾丸发育，特别是精子发生有关，其异常表达可能影响男性的生殖功能，因此该基因的研究可用于：The purpose of the present invention is: in view of the fact that the human testis development specific protein-19 gene is a brand-new gene discovered by the inventor, the current human knowledge and understanding of this gene is limited to the scientific research work done by the inventor. Since this gene is a gene related to the specific function of the testis, and its expression is low in embryos and high in adults, it is likely to be related to testis development, especially spermatogenesis, and its abnormal expression may affect male reproductive function, so this gene Research available for:
①通过制备该基因的融合蛋白，用于研究该基因与睾丸功能的关系，还可能成为一种治疗男性睾丸相关疾病的生物药品。① By preparing the fusion protein of the gene, it is used to study the relationship between the gene and testis function, and it may also become a biological drug for treating male testis-related diseases.
②制备特异性抗体：基因编码蛋白的特异性抗体是研究基因结构和功能的不可缺少的重要工具，人睾丸发育特异性蛋白-19基因编码蛋白的多克隆和单克隆抗体，可用作免疫组织化学染色、ELISA、免疫电镜、免疫共沉淀等多种根据免疫学原理设计的检测方法，可用于该基因编码蛋白在组织细胞中的定位和定量研究，也可用于各种生物样本(如血液、精液、尿液等)中的含量变化研究以及蛋白质-蛋白质相互作用研究等。因此，该抗体有可能用于制备与人睾丸发育特异性蛋白-19基因表达异常相关疾病的诊断试剂盒，并有可能用于制备抗生育药物。②Preparation of specific antibodies: specific antibodies to gene-encoded proteins are an indispensable and important tool for studying gene structure and function. Polyclonal and monoclonal antibodies to proteins encoded by the human testis development-specific protein-19 gene can be used as immune tissue Chemical staining, ELISA, immunoelectron microscopy, immunoprecipitation and other detection methods designed according to immunological principles can be used for the localization and quantitative research of the protein encoded by the gene in tissue cells, and can also be used for various biological samples (such as blood, Semen, urine, etc.) content change research and protein-protein interaction research, etc. Therefore, the antibody may be used to prepare a diagnostic kit for diseases related to the abnormal expression of the human testis development specific protein-19 gene, and may be used to prepare anti-fertility drugs.
③制备基因诊断芯片：将功能基因用于制备基因诊断芯片是基因开发研究的一个重要方面，在疾病诊断(如男性不育、性功能低下)和药物筛选等方面均具有重要意义。本发明技术方案1.人睾丸发育特异性蛋白-19基因融合蛋白的制备以人睾丸发育特异性蛋白-19基因开放阅读框的核苷酸序列与质粒pDESTTM15制备成GST-SP2-pDEST15表达质粒，在无NaCl的LB中30℃培养到0.5OD600，经0.3MNaCl诱导，超声粉碎后经GST亲和层析柱纯化，得到纯化的融合蛋白。2.人睾丸发育特异性蛋白-19基因编码蛋白特异性多克隆抗体③Preparation of genetic diagnostic chips: The use of functional genes in the preparation of genetic diagnostic chips is an important aspect of gene development research, and is of great significance in disease diagnosis (such as male infertility, low sexual function) and drug screening. Technical scheme of the present invention 1. Preparation of human testis development-specific protein-19 gene fusion protein The nucleotide sequence of the human testis development-specific protein-19 gene open reading frame and plasmid pDEST TM 15 are prepared into GST-SP2-pDEST15 expression The plasmid was cultured in NaCl-free LB at 30°C to 0.5OD600, induced by 0.3M NaCl, ultrasonically crushed, and then purified by GST affinity chromatography to obtain a purified fusion protein. 2. Human testis development specific protein-19 gene-encoded protein-specific polyclonal antibody
取融合蛋白与载体蛋白KLH(Keyhole Limpet Hymocyanin)结合，经透析后再与完全/不完全佐剂(Complete/Incomplete Freund’sAdjuvant)等量混合，免疫新西兰兔(背部皮下注射)，每隔3～4周激发注射一次，共三次，于三个月后取血分离血清。以免疫前动物血清作为对照做ELISA，测定各免疫兔血清中抗体滴度。筛选高滴度血清，进一步用抗原作竞争抑制免疫试验确定抗体的特异性。根据ELISA结果确定其用于免疫组织化学染色的稀释倍数为1∶200～500。3.人睾丸发育特异性蛋白-19基因编码蛋白特异性单克隆抗体Combine the fusion protein with the carrier protein KLH (Keyhole Limpet Hymocyanin), and then mix it with an equal amount of complete/incomplete adjuvant (Complete/Incomplete Freund's Adjuvant) after dialysis, and immunize New Zealand rabbits (subcutaneous injection in the back), every 3~ Inject once every 4 weeks for a total of three times, and blood was collected three months later to separate serum. ELISA was performed with the animal serum before immunization as a control, and the antibody titer in each immunized rabbit serum was determined. Screen high-titer sera, and further use the antigen as a competitive inhibition immunoassay to determine the specificity of the antibody. According to the results of ELISA, the dilution factor for immunohistochemical staining was determined to be 1:200-500. 3. Human testis development specific protein-19 gene-encoded protein-specific monoclonal antibody
取融合蛋白与载体蛋白KLH(Keyhole Limpet Hymocyanin)结合，经透析后再与完全/不完全佐剂(Complete/Incomplete Freund’sAdjuvant)混合，免疫Balb/C小鼠(腹腔内注射)，隔周一次，连续2-3次，融合前静脉加强一次，用ELISA方法证实抗体的产生后，取脾脏分离脾细胞，然后与骨髓瘤细胞融合产生杂交瘤细胞。阳性克隆经多次亚克隆，直至获得分泌抗人睾丸发育特异性蛋白-19的单克隆杂交瘤细胞株。4.人睾丸发育特异性蛋白-19基因用于制备睾丸功能基因表达芯片(1)以获取的人睾丸发育特异性蛋白-19基因的核苷酸序列设计引物，扩增全长的人睾丸发育特异性蛋白-19基因序列，用作点膜的样品。(2)用英国BioRobotics自动点膜仪将标本点在8×12cm尼龙膜上，每一标本点2个点，每点的DNA量约几ng。；阳性对照8个housekeeping genes(a.ribosomal protein S9；b.Actin gamma；c.glyceraldehyde-3-phosphate dehydrogenase；d.hypoxanthinephosphoribosyltransferase l；e.H.sapiens mRNA for 23KD highly basicprotein；f.ubiqnitin C；g.Phospholipase A2；h.ubiquitin carboxy I-ferminal esterase LI)。阴性对照加λ噬菌体DNA和P-blue质粒。(3)将含有该基因的芯片用于人睾丸发育特异性蛋白-19基因缺失的诊断和药物筛选33P标记：Combine the fusion protein with the carrier protein KLH (Keyhole Limpet Hymocyanin), and then mix it with complete/incomplete adjuvant (Complete/Incomplete Freund's Adjuvant) after dialysis, and immunize Balb/C mice (intraperitoneal injection), once every other week , 2-3 times in a row, and the vein was strengthened once before fusion. After confirming the production of antibodies by ELISA method, the spleen was taken to separate spleen cells, and then fused with myeloma cells to produce hybridoma cells. Positive clones were subcloned multiple times until a monoclonal hybridoma cell line secreting anti-human testis development-specific protein-19 was obtained. 4. The human testis development-specific protein-19 gene is used to prepare the testis functional gene expression chip (1) to design primers for the nucleotide sequence of the obtained human testis development-specific protein-19 gene to amplify the full-length human testis development Specific protein-19 gene sequence, used as a sample for dot membrane. (2) Use the British BioRobotics automatic film spotting instrument to spot the specimens on an 8×12 cm nylon membrane, 2 spots for each sample, and the amount of DNA in each spot is about a few ng. ; positive control 8 housekeeping genes (a.ribosomal protein S9; b.Actin gamma; c.glyceraldehyde-3-phosphate dehydrogenase; d.hypoxanthinephosphoribosyltransferase l; eHsapiens mRNA for 23KD highly basicprotein; f.ubiqnitin C; g.Phospholipase A2; h. ubiquitin carboxy I-ferminal esterase LI). Negative control plus lambda phage DNA and P-blue plasmid. (3) The chip containing the gene is used for the diagnosis and drug screening of human testis development specific protein-19 gene deletion 33 P marker:
抽提待检标本mRNA或DNA，用Random Primer标记法标记待检标本mRNA或DNA，作为杂交的探针。杂交：Extract the mRNA or DNA of the sample to be tested, and use the Random Primer labeling method to label the mRNA or DNA of the sample to be tested as a probe for hybridization. hybridization:
将点制好的尼龙膜标记探针杂交后，杂交炉(68℃)内烘干，用磷屏压片。信号扫描和分析：After hybridizing the prepared nylon membrane-labeled probes, dry them in a hybridization oven (68° C.), and press them with a phosphor screen. Signal Scanning and Analysis:
用记录仪分析杂交信号。根据杂交信号的强弱分析人睾丸发育特异性蛋白-19基因蛋白表达水平或人睾丸发育特异性蛋白-19基因的缺失。Hybridization signals were analyzed with a recorder. According to the strength of the hybridization signal, the protein expression level of human testis development specific protein-19 gene or the deletion of human testis development specific protein-19 gene was analyzed.
人睾丸发育特异性蛋白-19基因编码蛋白 Human Testis Development Specific Protein-19 Gene Encoded Protein
人睾丸发育特异性蛋白-19基因cDNA序列Human testis development specific protein-19 gene cDNA sequence
1 gggaagagtg ctgtggtgag tgagggattt tgccatggag aaggagaagg acccatagca1 gggaagagtg ctgtggtgag tgagggatt tgccatggag aaggagaagg acccatagca
61 gtttgtcagg ttcatggaat ccgagctgga cctaaatgac atcattcagg agatgcacgt61 gtttgtcagg ttcatggaat ccgagctgga cctaaatgac atcattcagg agatgcacgt
121 ggtggccacc atgccagacc tgtaccacct tctggtggag ctgaatgctg tacagtcgct121 ggtggccacc atgccagacc tgtaccacct tctggtggag ctgaatgctg tacagtcgct
181 tctcggcttg ctcggacacg ataatacaga tatcctttca gatctgacct cagtaggaga181 tctcggcttg ctcggacacg ataatacaga tatcctttca gatctgacct cagtaggaga
241 gctgacatgg tggatgggca ggtggtagca ctgctggtac agaatctgga gcgcctggat241 gctgacatgg tggatgggca ggtggtagca ctgctggtac agaatctgga gcgcctggat
301 gagtctgtga aagaggaggc agatggcgtc cacaacactc tggctattgt ggaaaacatg301 gagtctgtga aagaggaggc agatggcgtc cacaacactc tggctattgt ggaaaacatg
361 gctgagttcc ggcctgagat gtgtacagag ggtgcccagc agggtcttct acagtggctg361 gctgagttcc ggcctgagat gtgtacagag ggtgcccagc agggtcttct acagtggctg
421 ttgaagaggc tgaaggcaaa gatgcctttt gatgccaaca aactgtattg cagtgaagtg421 ttgaagaggc tgaaggcaaa gatgcctttt gatgccaaca aactgtattg cagtgaagtg
481 ctggccatat tgctccagga caatgatgaa aacagggaat tgcttgggga gctggatgga481 ctggccatat tgctccagga caatgatgaa aacagggaat tgcttgggga gctggatgga
541 atcgatgtgc ttcttcagca gttatccgtg tttaaaagac acaatcccag cacggctgag541 atcgatgtgc ttcttcagca gttatccgtg tttaaaagac acaatcccag cacggctgag
601 gagcaggaga tgatggagaa tctgtttgat tccctctgct cctgtctaat gcttagttcc601 gagcaggaga tgatggagaa tctgtttgat tccctctgct cctgtctaat gcttagttcc
661 aatcgtgagc gcttcctgaa gggcgagggt cttcagctga tgaatctcat gctcagggaa661 aatcgtgagc gcttcctgaa gggcgagggt cttcagctga tgaatctcat gctcagggaa
721 aagaagatct cccggagcag tgccctgaaa gtgctggacc atgccatgat tggccccgaa721 aagaagatct cccggagcag tgccctgaaa gtgctggacc atgccatgat tggccccgaa
781 ggcacagaca actgccataa gtttgttgac attcttggct tacgaaccat ctttcccctc781 ggcacagaca actgccataa gtttgttgac attcttggct tacgaaccat ctttcccctc
841 tttatgaaat ctcccaggaa gatcaagaaa gtgggaacca ctgagaagga acatgaagag841 tttatgaaat ctcccaggaa gatcaagaaa gtgggaacca ctgagaagga acatgaagag
901 catgtctgtt cgatcctggc ttccctcctg cggaacctga gagggcagca gcggacccgg901 catgtctgtt cgatcctggc ttccctcctg cggaacctga gagggcagca gcggacccgg
961 cttctgaata aattcactga aaatgacagt gagaaggttg acagactaat ggagttgcat961 cttctgaata aattcactga aaatgacagt gagaaggttg acagactaat ggagttgcat
1021 tttaaatatc tgggtgcaat gcaggtggcg gacaagaaga ttgaagggga aaaacacgac1021 tttaaatatc tgggtgcaat gcaggtggcg gacaagaaga ttgaagggga aaaacacgac
1081 atggtccggc gaggagagat catcgacaat gacaccgagg aggagttcta cctccggcgc1081 atggtccggc gaggagagat catcgacaat gacaccgagg aggagttcta cctccggcgc
1141 ctggatgcgg ggctctttgt tctccagcac atctgctaca tcatggccga gatctgcaat1141 ctggatgcgg ggctctttgt tctccagcac atctgctaca tcatggccga gatctgcaat
1201 gccaatgtcc cccagattcg ccagagggtt caccagatcc taaacatgcg aggaagctcc1201 gccaatgtcc cccagattcg ccagagggtt caccagatcc taaacatgcg aggaagctcc
1261 atcaaaattg tcaggcatat catcaaggag tatgcagaga acatcgggga cggccggagc1261 atcaaaattg tcaggcatat catcaaggag tatgcagaga acatcgggga cggccggagc
1321 ccggagttcc gggagaacga gcaaaagcgc atcctgggct tgctggagaa cttctagagg1321 ccggagttcc gggagaacga gcaaaagcgc atcctgggct tgctggagaa cttctagagg
1381 caccttggcc ctgcgcatca tggactctct cagcttccct cccaggatca gtttctacac1381 caccttggcc ctgcgcatca tggactctct cagcttccct cccaggatca gtttctacac
1441 aactctgtgt ggcttttgga caaattaaag ctagttttgg tttaaaaaaa aaaaaaaaaa1441 aactctgtgt ggcttttgga caaattaaag ctagttttgg tttaaaaaaaaaaaaaaaaa
1501 a人睾丸发育特异性蛋白-19基因编码蛋白氨基酸序列MVDGQVVALLVQNLERLDESVKEEADGVHNTLAIVENMAEFRPEMCTEGAQQGLLQWLLKRLKAKMPFDANKLYCSEVLAILLQDNDENRELLGELDGIDVLLQQLSVFKRHNPSTAEEQEMMENLFDSLCSCLMLSSNRERFLKGEGLQLMNLMLREKKISRSSALKVLDHAMIGPEGTDNCHKFVDILGLRTIFPLFMKSPRKIKKVGTTEKEHEEHVCSILASLLRNLRGQQRTRLLNKFTENDSEKVDRLMELHFKYLGAMQVADKKIEGEKHDMVRRGEIIDNDTEEEFYLRRLDAGLFVLQHICYIMAEICNANVPQIRQRVHQILNMRGSSIKIVRHIIKEYAENIGDGRSPEFRENEQKRILGLLENF1501 a人睾丸发育特异性蛋白-19基因编码蛋白氨基酸序列MVDGQVVALLVQNLERLDESVKEEADGVHNTLAIVENMAEFRPEMCTEGAQQGLLQWLLKRLKAKMPFDANKLYCSEVLAILLQDNDENRELLGELDGIDVLLQQLSVFKRHNPSTAEEQEMMENLFDSLCSCLMLSSNRERFLKGEGLQLMNLMLREKKISRSSALKVLDHAMIGPEGTDNCHKFVDILGLRTIFPLFMKSPRKIKKVGTTEKEHEEHVCSILASLLRNLRGQQRTRLLNKFTENDSEKVDRLMELHFKYLGAMQVADKKIEGEKHDMVRRGEIIDNDTEEEFYLRRLDAGLFVLQHICYIMAEICNANVPQIRQRVHQILNMRGSSIKIVRHIIKEYAENIGDGRSPEFRENEQKRILGLLENF
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01127197A CN1344735A (en) | 2001-09-13 | 2001-09-13 | Human testicular development specific protein-19 gene encoding protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN01127197A CN1344735A (en) | 2001-09-13 | 2001-09-13 | Human testicular development specific protein-19 gene encoding protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1344735A true CN1344735A (en) | 2002-04-17 |
Family
ID=4667183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN01127197A Pending CN1344735A (en) | 2001-09-13 | 2001-09-13 | Human testicular development specific protein-19 gene encoding protein |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1344735A (en) |
-
2001
- 2001-09-13 CN CN01127197A patent/CN1344735A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107478843A (en) | For the anti-CXCL9 of inflammatory disease, anti-CXCL10, anti-CXCL11, anti-cxcl 13, anti-CXCR3 and anti-CXCR5 reagents | |
| CN105548561B (en) | Diagnostic agent and diagnostic method for alzheimer's disease | |
| CN1344735A (en) | Human testicular development specific protein-19 gene encoding protein | |
| CN1344740A (en) | Human testicular development specific protein-20 gene encoding protein | |
| CN1382694A (en) | Human testis development specific protein-17 gene coding protein | |
| CN1318563A (en) | Human testicular development specific protein-6 gene encoded protein | |
| CN1344744A (en) | Human testicular development specific protein-27 gene encoding protein | |
| CN1318562A (en) | Human testicular development specific protein-14 gene encoded protein | |
| CN1309137A (en) | Human testicular gastrulation protein gene coded protein | |
| CN1309138A (en) | Human testicular cytodifferentiation related protein gene coded protein | |
| CN1344742A (en) | Human testicualr development specific protein-24 gene encoding protein | |
| CN1313342A (en) | Human testis lactate dehydrogenase A gene coded protein | |
| CN1318559A (en) | Human sperm skelemin gene encoded protein | |
| CN1318557A (en) | Human testicular specific protein-10 gene encoded protein | |
| CN1318560A (en) | Human testicular specific protein-1 gene encoded protein | |
| CN1318558A (en) | Human testicular development specific protein-12 gene encoded protein | |
| CN1318554A (en) | Human testicular development specific protein-11 gene encoded protein | |
| CN1344741A (en) | Human testicular development specific protein-21 gene encoding protein | |
| CN1319665A (en) | Human testics kinesin 9 gene coding protein | |
| CN1319660A (en) | Human testis specific protein kinase gene coding protein | |
| CN1319662A (en) | Human testicular ubiquitin specific proteinase-10 gene coding protein | |
| CN1316434A (en) | Human specific protein kinase-15 gene coding protein | |
| CN1316435A (en) | Human testicular development specificity protein-8 gene coding protein | |
| CN1313340A (en) | Human sperm-specific protein 2 gene coded protein | |
| CN114316041B (en) | Preparation method of NLS-RAR alpha monoclonal antibody, rapid detection card based on antibody and preparation method of rapid detection card |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |